Corporation, a biopharmaceutical company specializing in proprietary therapeutics with a market capitalization of $14 billion ...

Andrew Kuykendall, MD, discusses the rationale behind choosing to evaluate fedratinib in a phase 2 study for patients with atypical chronic myeloid leukemia, chronic neutrophilic leukemia, ...

Galapagos (0JXZ – Research Report) received a Sell rating and a €22.00 price target from Barclays analyst Emily Field today. The company’s ...

Combining ultraviolet (UV) phototherapy with the Janus kinase (JAK) inhibitor baricitinib (Olumiant) helped patients with ...

Combining baricitinib with narrowband UVB phototherapy led to significant repigmentation and enhanced quality of life in ...

Researchers report the ability of tofacitinib to reduce infection risk with SARS-CoV-2 in individuals who are deficient in ...

产品活性： Upadacitinib (ABT-494) 是一种高效的、具有口服活性的、选择性 Janus 激酶 1 (JAK1) 抑制剂 (IC50=43 nM)。Upadacitinib 对 JAK1 的选择性约为 JAK2 (200 nM）的 ...

Incyte CEO Hervé Hoppenot has promised investors that 2025 will be “a year that will be full of many defining catalysts” for ...

Leading biopharmaceutical company Pfizer has unveiled Cibinqo and Staquis, two innovative therapies designed to address eczema across its varying stages, now available in Malaysia. The announcement, ...

Incyte Highlights Commercial Growth, Clinical Progress and 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare ...

In a report released today, Emily Field from Barclays maintained a Hold rating on Galapagos (0JXZ – Research Report), with a price target of ...